deltatrials
Completed PHASE3 NCT00003093

Combination Chemotherapy in Treating Children With Neuroblastoma

Treatment for Infants and Children With Intermediate Risk Neuroblastoma: A Phase III Intergroup CCG/POG Study

Sponsor: Children's Oncology Group

Conditions Neuroblastoma
Interventions carboplatin conventional surgery cyclophosphamide doxorubicin hydrochloride etoposide filgrastim neoadjuvant therapy sargramostim
Updated 6 times since 2017 Last updated: Jul 31, 2014 Started: Mar 31, 1988 Primary completion: Sep 30, 2006 Completion: Jan 31, 2011

This PHASE3 trial investigates Neuroblastoma and is currently completed. Children's Oncology Group leads this study, which shows 6 recorded versions since 1988 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Mar 1988

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Children's Oncology Group
  • National Cancer Institute (NCI)
Data source: Children's Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States, Albany, United States, Albuquerque, United States, Amarillo, United States, Ann Arbor, United States, Asheville, United States, Atlanta, United States, Auckland, New Zealand, Augusta, United States, Austin, United States and 166 more location s